Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - ivacaftorum - granulat - ivacaftorum 50 mg, hypromellosi acetas succinas, natrii laurilsulfas, lactosum monohydricum 73.2 mg, mannitolum, sucralosum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas ad granulatum pro charta corresp. natrium 0.99 mg. - la fibrosi cistica - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - ivacaftorum - granulat - ivacaftorum 75 mg, hypromellosi acetas succinas, natrii laurilsulfas, lactosum monohydricum 109.8 mg, mannitolum, sucralosum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas ad granulatum pro charta corresp. natrium 1.49 mg. - la fibrosi cistica - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

westfalen gas schweiz gmbh - nitrogenii oxidum - inhalationsgas - nitrogenii oxidum 1000 ppm, nitrogenium, gasum inhalationis. - respirazione artificiale per i neonati - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - lumacaftorum, ivacaftorum - compresse rivestite con film - lumacaftorum 100 mg, ivacaftorum 125 mg, hypromellosi acetas succinas, natrii laurilsulfas, cellulosum microcristallinum, carmellosum natricum conexum, povidonum k 30, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 120, e 132, e 133, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum pro compresso obducto corresp. natrium 2.56 mg. - la fibrosi cistica - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - fibrosi cistica - altri prodotti per il sistema respiratorio - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - tezacaftorum, ivacaftorum - compresse rivestite con film - filmtablette morgendosis (tezacaftorum 100 mg / ivacaftorum 150 mg): tezacaftorum 100 mg, ivacaftorum 150 mg, hypromellosi acetas succinas, natrii laurilsulfas, hypromellosum, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, Überzug: hypromellosum, hydroxypropylcellulosum, talcum, e 171, e 172 (flavum) pro compresso obducto corresp. natrium 2.74 mg. filmtablette abenddosis (ivacaftorum 150 mg): ivacaftorum 150 mg, hypromellosi acetas succinas, natrii laurilsulfas, cellulosum microcristallinum, lactosum monohydricum 167.2 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 132, cera carnauba, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum pro compresso obducto corresp. natrium 1.82 mg. - il trattamento di fibrosi cistica - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - lumacaftorum, ivacaftorum - granulat - lumacaftorum 100 mg, ivacaftorum 125 mg, hypromellosi acetas succinas, natrii laurilsulfas, carmellosum natricum conexum, cellulosum microcristallinum, povidonum k 30 ad granulatum pro charta corresp. natrium 0.89 mg. - la fibrosi cistica - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - lumacaftorum, ivacaftorum - granulat - lumacaftorum 150 mg, ivacaftorum 188 mg, hypromellosi acetas succinas, natrii laurilsulfas, carmellosum natricum conexum, cellulosum microcristallinum, povidonum k 30 ad granulatum pro charta corresp. natrium 1.34 mg. - la fibrosi cistica - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - fibrosi cistica - altri prodotti per il sistema respiratorio - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - ivacaftorum - granulat - ivacaftorum 25 mg, hypromellosi acetas succinas, natrii laurilsulfas, lactosum monohydricum 36.6 mg, mannitolum, sucralosum, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas ad granulatum pro charta corresp. natrium 0.5 mg. - la fibrosi cistica - synthetika